Published in Cancer Lett on November 15, 1999
Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J (2005) 2.03
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int (2005) 1.83
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46
Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab (2010) 1.33
Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol (2011) 1.21
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol (2007) 1.19
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J (2014) 1.17
Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis (2004) 1.13
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm (2007) 1.10
Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem (2009) 1.09
Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother (2002) 1.07
The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol (2011) 1.06
ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem (2010) 1.05
The role of half-transporters in multidrug resistance. J Bioenerg Biomembr (2001) 1.04
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br J Pharmacol (2007) 1.03
Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2). Biochem J (2003) 1.01
Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol (2005) 0.99
The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep (2009) 0.96
Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC Gastroenterol (2008) 0.88
Small and Innovative Molecules as New Strategy to Revert MDR. Front Oncol (2014) 0.88
Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos (2007) 0.87
Evaluation of (99m)technetium-mebrofenin and (99m)technetium-sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytes. Pharm Res (2010) 0.85
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol (2009) 0.84
Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters. Br J Pharmacol (2007) 0.83
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One (2012) 0.82
Transport in technicolor: mapping ATP-binding cassette transporters in sea urchin embryos. Mol Reprod Dev (2014) 0.81
Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to Praziquantel. PLoS Negl Trop Dis (2014) 0.81
HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Res (2012) 0.80
Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol (2010) 0.80
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity. Br J Cancer (2002) 0.80
Assessment of drug transporter function using fluorescent cell imaging. Curr Protoc Toxicol (2013) 0.80
Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Invest New Drugs (2013) 0.79
Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. Antimicrob Agents Chemother (2009) 0.79
MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts. Oncotarget (2014) 0.78
Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats. Drug Metab Dispos (2008) 0.78
Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip. Cancer Lett (2015) 0.78
New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity. Drug Des Devel Ther (2013) 0.78
Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter. Curr Drug Metab (2015) 0.78
Anti-secretory properties of non-peptide somatostatin receptor agonists in isolated rat colon: luminal activity and possible interaction with P-glycoprotein. Br J Pharmacol (2002) 0.77
Alterations in P-Glycoprotein Expression and Function Between Macrophage Subsets. Pharm Res (2016) 0.77
The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro. Drug Metab Dispos (2013) 0.76
Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators. ACS Med Chem Lett (2013) 0.75
Synthesis of novel 1,8-acridinediones derivatives: Investigation of MDR reversibility on breast cancer cell lines T47D and tamoxifen-resistant T47D. Res Pharm Sci (2015) 0.75
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib. Pharmacol Res (2017) 0.75
Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position. Drug Des Devel Ther (2014) 0.75
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med (1999) 9.23
The development of close relationships in Japan and the United States: paths of symbiotic harmony and generative tension. Child Dev (2001) 4.96
Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol (2000) 4.10
Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol (2000) 3.10
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res (1999) 2.70
Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity (1995) 2.70
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer (2003) 2.33
Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes. Mol Cell Biol (1998) 2.32
The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J Cell Biol (1990) 2.32
Requirements for hyaluronic acid binding by CD44: a role for the cytoplasmic domain and activation by antibody. J Exp Med (1992) 2.30
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res (2001) 2.25
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood (2001) 2.25
The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci (2000) 2.21
Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol (2000) 2.16
MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to Gram-positive and Gram-negative bacteria and their cell wall components. J Immunol (2001) 2.12
Large plasma membrane disruptions are rapidly resealed by Ca2+-dependent vesicle-vesicle fusion events. J Cell Biol (1997) 2.01
B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med (1998) 2.00
Real-space observation of current-driven domain wall motion in submicron magnetic wires. Phys Rev Lett (2004) 1.99
Patching plasma membrane disruptions with cytoplasmic membrane. J Cell Sci (2000) 1.96
Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med (2001) 1.95
Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circ Res (1995) 1.94
Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol (2000) 1.94
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci (2001) 1.89
Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry (1990) 1.83
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta (2001) 1.82
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res (2001) 1.81
Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10. J Immunol (2000) 1.77
The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J Exp Med (2000) 1.71
Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene (2011) 1.71
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol (1994) 1.70
Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem (2000) 1.65
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res (1999) 1.62
P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer (2000) 1.60
Water transport by the Na+/glucose cotransporter under isotonic conditions. Biol Cell (1997) 1.59
Primary structure of AfsR, a global regulatory protein for secondary metabolite formation in Streptomyces coelicolor A3(2). Gene (1990) 1.57
A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood (1991) 1.56
Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab (2001) 1.54
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia (2007) 1.52
Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int Immunol (2001) 1.49
Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res (1986) 1.44
Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol (2000) 1.42
Response of the human neurogenic bladder to KCl, carbachol, ATP and CaCl2. Br J Urol (1993) 1.39
Effect of varicocelectomy on sperm parameters and pregnancy rate in patients with subclinical varicocele: a randomized prospective controlled study. J Urol (1996) 1.39
A short-term eradication therapy for Helicobacter pylori acute gastritis. J Gastroenterol Hepatol (2000) 1.38
Successful use of interferon for male infertility. Lancet (1994) 1.38
Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun (2001) 1.33
Toll-like receptors confer responsiveness to lipopolysaccharide from Porphyromonas gingivalis in human gingival fibroblasts. Infect Immun (2000) 1.33
Molecular characterization of type-specific capsular polysaccharide biosynthesis genes of Streptococcus agalactiae type Ia. J Bacteriol (1999) 1.32
Monoclonal antibodies to CD44 and their influence on hyaluronan recognition. J Cell Biol (1995) 1.31
RP105 is associated with MD-1 and transmits an activation signal in human B cells. Blood (1998) 1.29
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer (2008) 1.27
Immunological skin testing and interpretation: a plea for uniformity. Cancer (1979) 1.26
Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene (2001) 1.25
IL-5 induces a Pgp-1 (CD44) bright B cell subpopulation that is highly enriched in proliferative and Ig secretory activity and binds to hyaluronate. J Immunol (1990) 1.24
An amplification of IL-10 and TGF-beta in patients with IgG4-related tubulointerstitial nephritis. Clin Nephrol (2010) 1.24
Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A (1987) 1.22
Effect of intraocular lens fixation on the blood-aqueous barrier. Am J Ophthalmol (1984) 1.22
Proteolysis of human monocyte CD14 by cysteine proteinases (gingipains) from Porphyromonas gingivalis leading to lipopolysaccharide hyporesponsiveness. J Immunol (2000) 1.22
A gene cluster involved in aerial mycelium formation in Streptomyces griseus encodes proteins similar to the response regulators of two-component regulatory systems and membrane translocators. J Bacteriol (1993) 1.22
Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest (2000) 1.22
Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53. J Natl Cancer Inst (2000) 1.19
P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer (1991) 1.19
Regulatory roles for CD14 and phosphatidylinositol in the signaling via toll-like receptor 4-MD-2. Biochem Biophys Res Commun (2000) 1.18
Use of serum tumor markers in cancer diagnosis and management. Semin Oncol (1987) 1.17
Hepatitis A, B and C seroprevalence in Pakistan. Indian J Pediatr (1995) 1.17
Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun (2002) 1.17
Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem (1997) 1.16
The molecular mechanism of B cell activation by toll-like receptor protein RP-105. J Exp Med (1998) 1.15
Cloning of murine and rat vascular cell adhesion molecule-1. Biochem Biophys Res Commun (1992) 1.15
Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biol Chem (1989) 1.15
Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. Biochem Biophys Res Commun (1998) 1.14
Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst (1997) 1.13
Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry (1996) 1.13
Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem (1993) 1.13
Strong coupling between local moments and superconducting 'heavy' electrons in UPd2Al3. Nature (2001) 1.12
A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/toll-like receptor 4 signaling pathway. J Biol Chem (2000) 1.12
Plasma membrane disruption underlies injury of the corneal endothelium by ultrasound. Exp Eye Res (1999) 1.12
Characterization of autoantibody-secreting B cells in mice undergoing stimulatory (chronic) graft-versus-host reactions. Identification of a CD44hi population that binds specifically to hyaluronate. J Immunol (1991) 1.11
Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Genes Chromosomes Cancer (2000) 1.09
Infectivities of human and other primate lentiviruses are activated by desialylation of the virion surface. J Virol (1996) 1.08
Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell (2001) 1.08
Non-CD28 costimulatory molecules present in T cell rafts induce T cell costimulation by enhancing the association of TCR with rafts. J Immunol (2000) 1.08
Production of emotional facial expressions in European American, Japanese, and Chinese infants. Dev Psychol (1998) 1.07
Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res (1997) 1.07
The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population. Diabetologia (2005) 1.07
Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis. Cancer Res (1994) 1.07